1428065-56-8

Basic information

• Product Name: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine
• Synonyms: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine
• CAS NO: 1428065-56-8
• Molecular Weight: 271.362
• Mol File: 1428065-56-8.mol
• Article Data: 3

Chemical Properties

• CAS DataBase Reference: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine(CAS DataBase Reference)
• NIST Chemistry Reference: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine(1428065-56-8)
• EPA Substance Registry System: 5-((dimethylamino)methyl)-N-(4-methoxybenzyl)pyridin-3-amine(1428065-56-8)

Safety Data

• Hazardous Substances Data: 1428065-56-8(Hazardous Substances Data)

Upstream product

• 908864-98-2 1-(5-bromopyridin-3-yl)-N,N-dimethylmethanamine 
• 2393-23-9 4-methoxy-benzylamine 
• 113118-81-3 5-bromopyridine-3-carbaldehyde 

Relevant articles and documents

METHODS OF USING INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

This disclosure features the use of one or more indazole-3-carboxamide compounds or salts or analogs thereof, in the treatment of one or more diseases or conditions independently selected from the group consisting of a tendinopathy, dermatitis, psoriasis, morphea, ichthyosis, Raynaud's syndrome, and Darier's disease; and/or for promoting wound healing. The methods include administering to a subject (e.g., a subject in need thereof) a therapeutically effective amount of one or more indazole-3-carboxamide compounds or salts or analogs thereof as described anywhere herein.

INDAZOLE-3-CARBOXAMIDES AND THEIR USE AS WNT/B-CATENIN SIGNALING PATHWAY INHIBITORS

lndazole-3-carboxamide compounds for treating various diseases and pathologies are disclosed. More particularly, the present disclosure concerns the use of an indazole-3- carboxamide compound or analogs thereof, in the treatment of disorders characterized by the activation of Wnt pathway signaling (e.g., cancer, abnormal cellular proliferation, angiogenesis and osteoarthritis), the modulation of cellular events mediated by Wnt pathway signaling, as well as genetic diseases and neurological conditions/disorders/diseases due to mutations or dysregulation of the Wnt pathway and/or of one or more of Wnt signaling components. Also provided are methods for treating Wnt-related disease states.